Realizing the Potential for Biomanufacturing with DMC’s Made to Scale™ Technology

29/36   in the series Industry Interviews

Disclosure: This post is sponsored by DMC Biotechnologies and reflects their views, opinions, and insights.

The 2023 Metabolic Engineering Conference (ME15) takes place June 11–15 in Marina Bay Sands, Singapore. ME15 is the world-leading conference to share developments and achievements in the field. The conference enables participants to collectively explore how developments in metabolic engineering can advance diverse sectors across agriculture, biomanufacturing, medicine, and more. 

In this video, Kathryn Sheridan, CEO & Founder of Sustainability Consult, sits down to chat with Matt Lipscomb, CEO and Founder of DMC Biotechnologies. Together, they discuss the impact the biotechnology industry has, as well as its challenges and opportunities.

The full transcript of this interview can be found here.

Learn more about the Metabolic Engineering 15 and register today.  

Matt Lipscomb

Dr. Lipscomb, Ph.D. is CEO and Founder of DMC Biotechnologes, Inc. His career has included a range of development stages from early R&D to commercial deployment in a variety of sectors, including both industrial and pharmaceutical biotechnology. Read more.

Disclosure: This post is sponsored by DMC Biotechnologies and reflects their views, opinions, and insights.